Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30394540 | 1.00 | DDB1 (0.46) | DDB1CRBNKDM4ERORCPOLB | |
| SCHEMBL27702418 | 0.90 | PDE4B (0.53) | DDB1CRBNMEN1KMT2APDE4B | |
| SCHEMBL24323630 | 0.89 | HPGDS (0.50) | DDB1CRBNMEN1KMT2APDE4B | |
| SCHEMBL31726923 | 0.88 | DDB1 (0.42) | DDB1CRBNKDM4ERORCPOLB | |
| SCHEMBL25931442 | 0.87 | DDB1 (0.60) | DDB1CRBNKDM4EMEN1KMT2A | |
| SCHEMBL25297123 | 0.86 | POLB (0.43) | DDB1CRBNKDM4ERORCPOLB | |
| SCHEMBL31639929 | 0.85 | DDB1 (0.47) | DDB1CRBNKDM4ERORCPDE4B | |
| SCHEMBL24989018 | 0.84 | DDB1 (0.46) | DDB1CRBNKDM4ERORCPDE4B | |
| SCHEMBL25255965 | 0.84 | DDB1 (0.46) | DDB1CRBNKDM4ERORCPDE4B | |
| SCHEMBL20757383 | 0.84 | DDB1 (0.46) | DDB1CRBNKDM4ERORCPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| WO-2023247670-A1 | NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-28 | — | — | WO | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2012066061-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012066061-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012031004-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| CN-1956958-A | Aminopyridine derivatives as selective dopamine d3 agonists | PFIZER (US) | 2007-05-02 | — | — | CN | disclosed |
| EP-1758862-A1 | AMINOPYRIDINE DERIVATIVES AS SELECTIVE DOPAMINE D3 AGONISTS | Pfizer Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| US-20050288270-A1 | New aminopyridine derivatives and their use as pharmaceuticals | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005115985-A1 | AMINOPYRIDINE DERIVATIVES AS SELECTIVE DOPAMINE D3 AGONISTS | PFIZER LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288270-A1 | New aminopyridine derivatives and their use as pharmaceuticals | DRD2, DRD1, DRD3 | DDB1 3633/4885CRBN 4753/4885KDM4E 2165/4885 |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | DDB1 1719/4885CRBN 471/4885KDM4E 1806/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | DDB1 2404/4885CRBN 570/4885KDM4E 1570/4885 |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | DDB1 409/4885CRBN 1186/4885KDM4E 325/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | DDB1 2804/4885CRBN 1210/4885KDM4E 1137/4885 |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | DRD2, DRD1, DRD3 | DDB1 3890/4885CRBN 4695/4885KDM4E 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.